VetaMeg: Product Information

VETAMEG- flunixin meglumine paste
Aspen Veterinary Resources

ANADA 200-581, Approved by FDA

VetaMeg®  Equine Paste

(flunixin meglumine)




WARNING: Do not use in horses intended for human consumption.

ACTIVITY: Flunixing meglumine is a potent, nonnarcotic, nonsteroidalm analgesic agent with anti-inflammatory and antipyretic activity, It is significantly more potent than pentazocine, meperidine, and codeine as an analgensic in the rat yeast paw test. Oral studies in the horse show onset of flunixin activity occurs withing 2 hours of administration. Peak response occurs between 12 and 16 hours and duration of activity is 24-36 hours.

CONTRAINDICATIONS: There are no known contraindications to this drug when used as directed.

PRECAUTIONS: The effect of flunixin meglumine on pregnancy has not been determined. Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of flunixin meglumine.

SIDE EFFECTS: During field studies with flunixin meglumine, no significant side effects were reported.

DOSAGE AND ADMINISTRATION: The recommended dose of flunixin meglumine is 0.5 mg per lb of body weight once daily. The VetaMeg® Equine Paste syringe, calibrated in twelve 250-lb weight increments, delivers 125 mg of flunixin for each 250 lbs (see dosage table). One syringe will treat a 1000-lb horse once daily for 3 days, or three 1000-lb horses one time.


Syringe Mark* Horse Weight (lbs) VetaMeg™ Equine Paste Delevered (g) mg Flunixin Delivered
250 250 2.5 125
500 500 5.0 250
750 750 7.5 375
1000 1000 10.0 500

* Use dial edge nearest syringe barrel to mark dose.

The paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger.

Treatment may be given initially by intravenous or intramuscular injection of VetaMeg™ Injectable Solution, followed by VetaMeg™ Equine Paste on Days 2 to 5. Flunixin meglumine treatment should not exceed 5 consecutive days.

TOXICITY: No toxic effects were observed in rats given oral flunixin meglumine 2 mg/kg per day for 42 days. Higher doses produced ulceration of the gastrointestinal tract. The emetic dose in dogs is between 150 and 250 mg/kg. Flunixin was well tolerated in monkeys dosed daily with 4 mg/kg for 56 days. No adverse effects occurred in horses dosed orally with 1.0 or 1.5 mg/lb for 5 consecutive days.

WARNING: D o not use in horses intended for human consumption.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS: For the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.

DOSE: 0.5 mg per pound of body weight per day for up to 5 days. Each calibration on the syringe’ doses 250 lbs of body weight. Administer orally by inserting the nozzle of the syringe through the interdental space and depositing the required amount of paste on the back of the tongue by depressing the plunger. *Use dial edge nearest syringe barrel to mark dose.

STORAGE: Store at 20°C — 25°C (68°F — 77°F); excursions permitted between 15°C — 30°C (between 59°F — 86°F)

See product information sheet for additional information.

image description
(click image for full-size original)

image description
(click image for full-size original)
flunixin meglumine paste
Product Information
Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:46066-503
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
# Item Code Package Description Multilevel Packaging
1 NDC:46066-503-01 30 g in 1 SYRINGE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANADA ANADA200581 02/26/2015
Labeler — Aspen Veterinary Resources (627265361)
Registrant — Bimeda Inc. (060492923)
Name Address ID/FEI Operations
Bimeda-MTC 256232216 manufacture

Revised: 02/2021 Aspen Veterinary Resources provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

Our database mirrors the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. provides the full animal health subset of the FDA's repository. Veterinary information provided here is not intended as a substitute for direct consultation with a qualified veterinary professional.

Terms of Use | Copyright © 2021. All Rights Reserved.